August proved to be a very busy month on the regulatory front, in terms of Novel Drug approvals, the ongoing efforts to restrict opioid abuse, and new efforts to encourage further advances in the rapidly evolving field of gene therapy. Now, let's take a look at the biotech stocks awaiting FDA decision in September.
from RTT - Biotech https://ift.tt/2NA4aMG
via IFTTT
No comments:
Post a Comment